CA2064373A1 - Piperidine derivatives - Google Patents

Piperidine derivatives

Info

Publication number
CA2064373A1
CA2064373A1 CA 2064373 CA2064373A CA2064373A1 CA 2064373 A1 CA2064373 A1 CA 2064373A1 CA 2064373 CA2064373 CA 2064373 CA 2064373 A CA2064373 A CA 2064373A CA 2064373 A1 CA2064373 A1 CA 2064373A1
Authority
CA
Canada
Prior art keywords
piperidine derivatives
piperidine
trisubstitutedpiperidinyl
alkylcarboxylates
carboxylates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2064373
Other languages
French (fr)
Other versions
CA2064373C (en
Inventor
Buddy Eugene Cantrell
Dennis Michael Zimmerman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Buddy Eugene Cantrell
Dennis Michael Zimmerman
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Buddy Eugene Cantrell, Dennis Michael Zimmerman, Eli Lilly And Company filed Critical Buddy Eugene Cantrell
Publication of CA2064373A1 publication Critical patent/CA2064373A1/en
Application granted granted Critical
Publication of CA2064373C publication Critical patent/CA2064373C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Abstract

3,4,4-trisubstitutedpiperidinyl-N-alkyl-carboxylates and intermediates for their preparation are provided. These piperidine-N-alkylcarboxylates are useful as peripheral opioid antagonists.
CA 2064373 1991-03-29 1992-03-27 Piperidine derivatives Expired - Lifetime CA2064373C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66704291A 1991-03-29 1991-03-29
US677,042 1991-03-29

Publications (2)

Publication Number Publication Date
CA2064373A1 true CA2064373A1 (en) 1992-09-30
CA2064373C CA2064373C (en) 2005-08-23

Family

ID=24676573

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2064373 Expired - Lifetime CA2064373C (en) 1991-03-29 1992-03-27 Piperidine derivatives

Country Status (1)

Country Link
CA (1) CA2064373C (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004091622A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
US7563899B2 (en) 2005-05-25 2009-07-21 Progenics Pharmaceuticals, Inc. (S)-N-methylnaltrexone
US7674904B2 (en) 2005-05-25 2010-03-09 Progenics Pharmaceuticals, Inc. Synthesis of R-N-methylnaltrexone
US8247425B2 (en) 2008-09-30 2012-08-21 Wyeth Peripheral opioid receptor antagonists and uses thereof
US8338446B2 (en) 2007-03-29 2012-12-25 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
US8471022B2 (en) 2008-02-06 2013-06-25 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone
US8546418B2 (en) 2007-03-29 2013-10-01 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
US8552025B2 (en) 2003-04-08 2013-10-08 Progenics Pharmaceuticals, Inc. Stable methylnaltrexone preparation
US9102680B2 (en) 2007-03-29 2015-08-11 Wyeth Llc Crystal forms of (R)-N-methylnaltrexone bromide and uses thereof
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662390B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9675602B2 (en) 2005-03-07 2017-06-13 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9717725B2 (en) 2005-03-07 2017-08-01 The University Of Chicago Use of opioid antagonists
US10383869B2 (en) 2008-03-21 2019-08-20 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9669096B2 (en) 2003-04-08 2017-06-06 Progenics Pharmaceuticals, Inc. Stable pharmaceutical formulations of methylnaltrexone
US8552025B2 (en) 2003-04-08 2013-10-08 Progenics Pharmaceuticals, Inc. Stable methylnaltrexone preparation
WO2004091622A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
US10376584B2 (en) 2003-04-08 2019-08-13 Progenics Pharmaceuticals, Inc. Stable pharmaceutical formulations of methylnaltrexone
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9717725B2 (en) 2005-03-07 2017-08-01 The University Of Chicago Use of opioid antagonists
US9662390B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9675602B2 (en) 2005-03-07 2017-06-13 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8003794B2 (en) 2005-05-25 2011-08-23 Progenics Pharmaceuticals, Inc. (S)-N-methylnaltrexone
US8343992B2 (en) 2005-05-25 2013-01-01 Progenics Pharmaceuticals, Inc. Synthesis of R-N-methylnaltrexone
US7674904B2 (en) 2005-05-25 2010-03-09 Progenics Pharmaceuticals, Inc. Synthesis of R-N-methylnaltrexone
US7563899B2 (en) 2005-05-25 2009-07-21 Progenics Pharmaceuticals, Inc. (S)-N-methylnaltrexone
US9597327B2 (en) 2005-05-25 2017-03-21 Progenics Pharmaceuticals, Inc. Synthesis of (R)-N-methylnaltrexone
US8916581B2 (en) 2005-05-25 2014-12-23 Progenics Pharmaceuticals, Inc. (S)-N-methylnaltrexone
US8853232B2 (en) 2007-03-29 2014-10-07 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
US8338446B2 (en) 2007-03-29 2012-12-25 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
US9102680B2 (en) 2007-03-29 2015-08-11 Wyeth Llc Crystal forms of (R)-N-methylnaltrexone bromide and uses thereof
US9879024B2 (en) 2007-03-29 2018-01-30 Progenics Pharmaceuticals., Inc. Crystal forms of (R)-N-methylnaltrexone bromide and uses thereof
US8772310B2 (en) 2007-03-29 2014-07-08 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
US8546418B2 (en) 2007-03-29 2013-10-01 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
US8916706B2 (en) 2008-02-06 2014-12-23 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone
US8471022B2 (en) 2008-02-06 2013-06-25 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone
US10383869B2 (en) 2008-03-21 2019-08-20 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
US9180125B2 (en) 2008-09-30 2015-11-10 Wyeth, Llc Peripheral opioid receptor antagonists and uses thereof
US8420663B2 (en) 2008-09-30 2013-04-16 Wyeth Peripheral opioid receptor antagonists and uses thereof
US8455644B2 (en) 2008-09-30 2013-06-04 Wyeth Peripheral opioid receptor antagonists and uses thereof
US9724343B2 (en) 2008-09-30 2017-08-08 Wyeth, Llc Peripheral opioid receptor antagonists and uses thereof
US9492445B2 (en) 2008-09-30 2016-11-15 Wyeth, Llc Peripheral opioid receptor antagonists and uses thereof
US8247425B2 (en) 2008-09-30 2012-08-21 Wyeth Peripheral opioid receptor antagonists and uses thereof
US8822490B2 (en) 2008-09-30 2014-09-02 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof

Also Published As

Publication number Publication date
CA2064373C (en) 2005-08-23

Similar Documents

Publication Publication Date Title
AU644051B2 (en) Piperidine derivatives
AU5374294A (en) 4-carboxoamido piperidine derivatives, intermediates and use as neurokinin antagonists
AU7655094A (en) Benzofuran derivatives as tachykinin antagonists
AU5704894A (en) Phenyl derivatives useful as tachykinin antagonists
AU5333596A (en) 3-benzylamino-2-phenylpiperidines as neurokinin antagonists
AU5342894A (en) Tachykinin antagonists
AU4718093A (en) Substituted amines as tachykinin receptor antagonists
AU6991996A (en) 2(1H)-quinolone derivatives as serotonin antagonists
AU5520298A (en) Spiro-substituted azacyclic-substituted piperazino derivatives as neurokinin antagonists
EP0707581A1 (en) Indoline derivatives as 5ht 2c? antagonists
AU4261293A (en) 1-piperazineacetic derivatives as fibrinogen receptor antagonists
CA2064373A1 (en) Piperidine derivatives
AU2759892A (en) N-aryl-n1-azabicyclo-ureas as 5-ht3 antagonists
AU627576B2 (en) Substituted 2,4 - diamino-quinazoline derivatives
AU4668289A (en) Heteroazabenzobicyclic carboxamide 5-ht3, antagonists
AU8442791A (en) 1,2,5,6-tetrahydropyridine oxime derivatives
EP0708765A4 (en) Substituted piperazinylcamphor derivatives as oxytocin antagonists
AU4991797A (en) Piperazino derivatives as neurokinin antagonists
AU1606197A (en) Novel piperidine derivatives 4-substituted by an imidazolidin-2-on-1-yl-ethyl, tetrahydropyrimidin-2-on-1-yl-ethyl and 1,3-diazepin-2-on-1-yl-ethyl group, and use thereof as alpha2-adrenergic receptor antagonists
HU9402436D0 (en) 2,6-method-2h-quinolizin derivative as 5-ht3-receptor antagonist
AU6506594A (en) 3-phenyl-1,2,5,6-tetrahydropyridine derivatives as sedatives
AU4264096A (en) 3,4-dihydro-2,5,7,8-tetramethyl-benzopyran-6-ol derivatives for use as drugs
GR3033237T3 (en) Quinoline derivatives as leukoriene antagonists.
MY111366A (en) Piperdine derivatives.
AU635517B2 (en) 8,9-annelated-1,2,3,4-tetrahydro-beta-carboline derivatives

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry